Katka Szilagyi1, Alexander B Meijer2, Annette E Neele3, Paul Verkuijlen3, Michael Leitges4, Sandrine Dabernat5, Elisabeth Förster-Waldl6, Kaan Boztug7, Alexandre Belot8, Taco W Kuijpers9, Georg Kraal10, Menno P J de Winther11, Timo K van den Berg3. 1. Department of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Plesmanlaan 125, Amsterdam 1066CX, The Netherlands k.szilagyi@sanquin.nl. 2. Department of Plasma Proteins, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 3. Department of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Plesmanlaan 125, Amsterdam 1066CX, The Netherlands. 4. The Biotechnology Centre of Oslo, University of Oslo, Oslo, Norway. 5. INSERM U1035, Université Bordeaux Segalen, Bordeaux, France. 6. Divison of Neonatology, Paediatric Intensive Care and Neuropaediatrics, Department of Paediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria. 7. Divison of Neonatology, Paediatric Intensive Care and Neuropaediatrics, Department of Paediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria. 8. Hôpital Femme Mère Enfant, Hospices Civils de Lyon and Université de Lyon, Lyon, France. 9. Department of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Plesmanlaan 125, Amsterdam 1066CX, The Netherlands Department of Pediatric Hematology, Immunology and Infectious Disease, Emma Children's Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 10. Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands. 11. Department of Medical Biochemistry, Experimental Vascular Biology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Abstract
AIMS: Uptake of oxidized lipoprotein particles (oxLDL) and foam cell formation by macrophages is one of the first steps in the development of atherosclerosis. Recently, protein kinase C δ (PKCδ) has been implicated as a regulator of oxLDL uptake and foam cell formation via down-regulation of PKCβ and scavenger receptors CD36 and SR-A expression. Here, we describe studies in which we have re-evaluated the role of PKCδ in oxLDL uptake and foam cell formation. METHODS AND RESULTS: PKCδ expression was silenced in the human monocytic cell lines and also in primary human monocytes to analyse oxLDL uptake and CD36 expression. Additionally, bone marrow-derived macrophages of PKCδ knockout mice and macrophages cultured from patients with rare null mutations in the PRKCD gene were tested for uptake of oxLDL and foam cell formation. Expression of scavenger receptor CD36 was determined and levels of PKCβ isoforms were quantified. Neither a reduction in PKCδ levels nor its complete absence resulted in a detectable effect on the uptake of oxLDL and the formation of foam cells. CONCLUSION: PKCδ is dispensible for oxLDL uptake and foam cell formation by monocytes and macrophages. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Uptake of oxidized lipoprotein particles (oxLDL) and foam cell formation by macrophages is one of the first steps in the development of atherosclerosis. Recently, protein kinase C δ (PKCδ) has been implicated as a regulator of oxLDL uptake and foam cell formation via down-regulation of PKCβ and scavenger receptors CD36 and SR-A expression. Here, we describe studies in which we have re-evaluated the role of PKCδ in oxLDL uptake and foam cell formation. METHODS AND RESULTS: PKCδ expression was silenced in the human monocytic cell lines and also in primary human monocytes to analyse oxLDL uptake and CD36 expression. Additionally, bone marrow-derived macrophages of PKCδ knockout mice and macrophages cultured from patients with rare null mutations in the PRKCD gene were tested for uptake of oxLDL and foam cell formation. Expression of scavenger receptor CD36 was determined and levels of PKCβ isoforms were quantified. Neither a reduction in PKCδ levels nor its complete absence resulted in a detectable effect on the uptake of oxLDL and the formation of foam cells. CONCLUSION: PKCδ is dispensible for oxLDL uptake and foam cell formation by monocytes and macrophages. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: S P Parihar; M Ozturk; M J Marakalala; D T Loots; R Hurdayal; D Beukes Maasdorp; M Van Reenen; D E Zak; F Darboe; A Penn-Nicholson; W A Hanekom; M Leitges; T J Scriba; R Guler; F Brombacher Journal: Mucosal Immunol Date: 2017-08-09 Impact factor: 7.313
Authors: Gijs Kooij; Rens Braster; Jasper J Koning; Lisa C Laan; Sandra J van Vliet; Tamara Los; Anne Marieke Eveleens; Susanne M A van der Pol; Elisabeth Förster-Waldl; Kaan Boztug; Alexandre Belot; Katka Szilagyi; Timo K van den Berg; Jaap D van Buul; Marjolein van Egmond; Helga E de Vries; Richard D Cummings; Christine D Dijkstra; Irma van Die Journal: Acta Neuropathol Commun Date: 2015-07-25 Impact factor: 7.801
Authors: Yuan Tian; Bin Yang; Weinan Qiu; Yajing Hao; Zhenxing Zhang; Bo Yang; Nan Li; Shuqun Cheng; Zhangjun Lin; Yao-Cheng Rui; Otto K W Cheung; Weiqin Yang; William K K Wu; Yue-Sun Cheung; Paul B S Lai; Jianjun Luo; Joseph J Y Sung; Runsheng Chen; Hong-Yang Wang; Alfred S L Cheng; Pengyuan Yang Journal: Nat Commun Date: 2019-07-29 Impact factor: 14.919
Authors: Li-Na Miao; Deng Pan; Junhe Shi; Jian-Peng Du; Peng-Fei Chen; Jie Gao; Yanqiao Yu; Da-Zhuo Shi; Ming Guo Journal: Front Cardiovasc Med Date: 2022-02-15